Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00103298
Recruitment Status : Completed
First Posted : February 8, 2005
Last Update Posted : June 20, 2013
Information provided by:
National Cancer Institute (NCI)

February 7, 2005
February 8, 2005
June 20, 2013
December 2004
Not Provided
Response and duration of response
Not Provided
Complete list of historical versions of study NCT00103298 on Archive Site
  • Patterns of recurrence
  • Progression-free and overall survival
  • Correlation of health-related quality of life with length of survival
Not Provided
Not Provided
Not Provided
Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
A Phase II Trial of Isolated Hepatic Perfusion (IHP) and Systemic FOLFOX4 for Subjects With Metastatic Unresectable Colorectal Cancers of the Liver With ≥ 40% Hepatic Tumor Burden

RATIONALE: Drugs used in chemotherapy, such as melphalan, leucovorin, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving the drugs in different ways may kill more tumor cells.

PURPOSE: This phase II trial is studying how well isolated hepatic perfusion with melphalan followed by combination chemotherapy works in treating patients with unresectable liver metastases from colorectal cancer.



  • Determine the response and duration of response in patients with previously untreated unresectable liver metastases secondary to colorectal cancer treated with isolated hepatic perfusion with melphalan followed by leucovorin calcium, oxaliplatin, and fluorouracil.


  • Determine the patterns of recurrence (liver vs systemic) in patients treated with this regimen.
  • Determine progression-free and overall survival of patients treated with this regimen.
  • Correlate health-related quality of life with length of survival of patients treated with this regimen.

OUTLINE: Patients undergo exploratory laparotomy. Patients with evidence of carcinomatosis not previously visualized on scans but found on surgical exploration are removed from the study. All other patients then undergo isolated hepatic perfusion (IHP). Once IHP is established, melphalan is administered intra-arterially over 3-5 minutes and then circulated throughout the liver for 1 hour. Approximately 6-12 weeks later, patients receive systemic chemotherapy comprising oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV over 2 hours and fluorouracil IV continuously over 22 hours on days 1-2. Courses with systemic chemotherapy repeat every 14 days for up to 1 year in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, after laparotomy, after completion of systemic chemotherapy, and then every 6 months thereafter.

After completion of study treatment, patients are followed every 3 months for 1 year, every 3-4 months for 2 years, and then every 6 months until disease progression.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 2-3 years.

Phase 2
Masking: None (Open Label)
Primary Purpose: Treatment
  • Colorectal Cancer
  • Metastatic Cancer
  • Drug: FOLFOX regimen
  • Drug: fluorouracil
  • Drug: isolated perfusion
  • Drug: leucovorin calcium
  • Drug: melphalan
  • Drug: oxaliplatin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
Not Provided
July 2006
Not Provided


  • Histologically or cytologically confirmed colorectal cancer

    • Metastatic disease limited to the parenchyma of the liver

      • No evidence of unresectable extrahepatic disease by preoperative radiology

        • Limited extra-hepatic disease and dominant life-limiting liver disease allowed provided extra-hepatic sites are treatable by local ablative measures (e.g., surgical resection or external beam radiotherapy)
  • At least 40% hepatic replacement by tumor by axial CT scan or MRI
  • Unresectable liver metastases, defined by 1 of the following:

    • More than 3 sites of disease in the liver
    • Bilobar disease
    • Tumor abutting major vascular or ductal structures
  • Measurable disease
  • Previously untreated disease



  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • Not specified


  • Hematocrit > 27.0%
  • WBC > 3,000/mm^3
  • Platelet count > 100,000/mm^3


  • Bilirubin < 2.0 mg/dL
  • PT < 2 seconds above upper limit of normal
  • Elevated transaminase levels allowed if due to liver metastases
  • No cirrhosis by biopsy
  • No significant portal hypertension as manifested by any of the following:

    • Ascites
    • Esophageal varices by endoscopy
    • Significant collateral vessels around the organs drained by the portal venous system by radiography
  • No chronic active hepatitis

    • Hepatitis B and C surface antigen negative
  • No history of veno-occlusive disease


  • Creatinine ≤ 1.5 mg/dL OR
  • Creatinine clearance > 60 mL/min


  • No ischemic cardiac disease
  • No history of congestive heart failure
  • LVEF > 40% by echocardiogram or stress thallium scan (for patients with cardiac disease)


  • No chronic obstructive pulmonary disease or other chronic pulmonary disease
  • Pulmonary function tests ≥ 50% of predicted (for patients with pulmonary disease)


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Weight > 30 kg
  • No active infection
  • No peripheral neuropathy ≥ grade 2


Biologic therapy

  • Not specified


  • Prior adjuvant chemotherapy (including leucovorin calcium, oxaliplatin, and fluorouracil) allowed provided it was administered > 6 months before liver metastases were diagnosed

Endocrine therapy

  • Not specified


  • More than 4 weeks since prior radiotherapy for this malignancy and recovered


  • Not specified


  • No concurrent chronic anticoagulation therapy
  • No concurrent immunosuppressive drugs
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Not Provided
National Cancer Institute (NCI)
Not Provided
Study Chair: H. Richard Alexander, MD, FACS NCI - Surgery Branch
National Cancer Institute (NCI)
February 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP